Literature DB >> 26849515

Evolving Japanese regulations on companion diagnostics.

Sumimasa Nagai1, Masaaki Urata1, Hiroyuki Sato1, Motoki Mikami1, Wataru Kuga1, Reiko Yanagihara1, Daisei Miyamoto1, Yuka Suzuki1, Mayumi Shikano1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26849515     DOI： 10.1038/nbt.3478

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.

Authors:  Francesco Pignatti; Falk Ehmann; Robert Hemmings; Bertil Jonsson; Micha Nuebling; Marisa Papaluca-Amati; Martin Posch; Guido Rasi
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531

2.  FDA perspective on companion diagnostics: an evolving paradigm.

Authors:  Elizabeth A Mansfield
Journal:  Clin Cancer Res       Date:  2014-03-15       Impact factor: 12.531
  2 in total
  2 in total

Review 1.  Companion diagnostics-a tool to improve pharmacotherapy.

Authors:  Jan Trøst Jørgensen; Maria Hersom
Journal:  Ann Transl Med       Date:  2016-12

Review 2.  A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies.

Authors:  Victoria Serelli-Lee; Kazumi Ito; Akira Koibuchi; Takahiko Tanigawa; Takayo Ueno; Nobuko Matsushima; Yasuhiko Imai
Journal:  J Pers Med       Date:  2022-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.